Aleglitazar | RG-1439 | RO-0728804 | CAS#475479-34-6 | PPARα and PPARγ agonist

MedKoo Cat#: 319594 | Name: Aleglitazar

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aleglitazar, also known as RG-1439 or RO-0728804, is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, Aleglitazar improves Insulin Sensitivity, Glucose Control and Lipids in People with Type 2 Diabetes.

Chemical Structure

Aleglitazar

CAS#475479-34-6

Theoretical Analysis

MedKoo Cat#: 319594

Name: Aleglitazar

CAS#: 475479-34-6

Chemical Formula: C24H23NO5S

Exact Mass: 437.1297

Molecular Weight: 437.51

Elemental Analysis: C, 65.89; H, 5.30; N, 3.20; O, 18.28; S, 7.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RO-0728804; RO 0728804; RO0728804; RG-1439; R-1439; R 1439; R1439; Aleglitazar.

IUPAC/Chemical Name

(S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo[b]thiophen-7-yl)propanoic acid

InChi Key

DAYKLWSKQJBGCS-NRFANRHFSA-N

InChi Code

InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1

SMILES Code

CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 437.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Stirban AO, Andjelkovic M, Heise T, Nosek L, Fischer A, Gastaldelli A, Herz M. Aleglitazar, a Dual Peroxisome Proliferator-Activated Receptor -α/γ Agonist, Improves Insulin Sensitivity, Glucose Control and Lipids in People with Type 2 Diabetes: Findings from a Randomized, Double-blind Trial. Diabetes Obes Metab. 2015 Dec 11. doi: 10.1111/dom.12620. [Epub ahead of print] PubMed PMID: 26663152. 2: Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J. 2015 Jul;170(1):117-22. doi: 10.1016/j.ahj.2015.03.021. Epub 2015 Apr 2. PubMed PMID: 26093872. 3: Henry RR, Buse JB, Wu H, Durrwell L, Mingrino R, Jaekel K, El Azzouzi B, Andjelkovic M, Herz M. Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials. Diabetes Obes Metab. 2015 Jun;17(6):560-5. doi: 10.1111/dom.12455. Epub 2015 Apr 8. PubMed PMID: 25728612. 4: Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180. PubMed PMID: 25407798; PubMed Central PMCID: PMC4364102. 5: Mearns BM. Acute coronary syndromes: Aleglitazar trial findings reported. Nat Rev Cardiol. 2014 Jun;11(6):311. doi: 10.1038/nrcardio.2014.53. Epub 2014 Apr 15. PubMed PMID: 24736759. 6: Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321. PubMed PMID: 24682069. 7: Werner CM, Schirmer SH, Gensch C, Pavlickova V, Pöss J, Wright MB, Böhm M, Laufs U. The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis. Br J Pharmacol. 2014 May;171(10):2685-703. doi: 10.1111/bph.12608. PubMed PMID: 24467636; PubMed Central PMCID: PMC4009009. 8: Sanwald-Ducray P, Jamois C, Banken L. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects. J Cardiovasc Pharmacol. 2014 Feb;63(2):152-7. doi: 10.1097/FJC.0000000000000033. PubMed PMID: 24157957. 9: Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013. Epub 2013 Jul 26. PubMed PMID: 24016490. 10: Bénardeau A, Verry P, Atzpodien EA, Funk JM, Meyer M, Mizrahi J, Winter M, Wright MB, Uhles S, Sebokova E. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2013 Feb;15(2):164-74. doi: 10.1111/dom.12006. Epub 2012 Oct 3. PubMed PMID: 22958363. 11: Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11. doi: 10.1002/cmdc.201100598. Epub 2012 Apr 4. PubMed PMID: 22489042; PubMed Central PMCID: PMC3504387. 12: Sturm S, Seiberling M, Weick I, Paehler A, Funk C, Ruf T. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers. Clin Ther. 2012 Feb;34(2):420-9. doi: 10.1016/j.clinthera.2011.12.009. Epub 2012 Jan 15. PubMed PMID: 22244809. 13: Sturm S, Bentley D, Jordan P, Russell-Yarde F, Ruf T. No evidence of QT prolongation with supratherapeutic doses of aleglitazar. J Cardiovasc Pharmacol. 2012 Mar;59(3):288-97. doi: 10.1097/FJC.0b013e3182411e67. PubMed PMID: 22113345. 14: Younk LM, Uhl L, Davis SN. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):753-63. doi: 10.1517/17425255.2011.579561. Epub 2011 Apr 27. Review. PubMed PMID: 21521130. 15: Hansen BC, Tigno XT, Bénardeau A, Meyer M, Sebokova E, Mizrahi J. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol. 2011 Jan 20;10:7. doi: 10.1186/1475-2840-10-7. PubMed PMID: 21251281; PubMed Central PMCID: PMC3037308. 16: Foley-Comer AJ, Young AM, Russell-Yarde F, Jordan P. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Expert Opin Investig Drugs. 2011 Jan;20(1):3-12. doi: 10.1517/13543784.2010.539559. Epub 2010 Nov 29. PubMed PMID: 21114416. 17: Lecka-Czernik B. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs. 2010 Nov;13(11):793-801. Review. PubMed PMID: 21046527. 18: Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Wieczorek Kirk D. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol. 2011 Sep 1;151(2):136-42. doi: 10.1016/j.ijcard.2010.08.037. Epub 2010 Sep 15. PubMed PMID: 20837369. 19: Cavender MA, Lincoff AM. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000. PubMed PMID: 20653327. 20: Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther. 2010 Aug;88(2):197-203. doi: 10.1038/clpt.2009.259. Epub 2010 Mar 24. PubMed PMID: 20336066.